Subjects taking any lipid modification therapy, including but not limited to statins, fibrates and bile acid sequestrants. 
Subjects taking fish oil or any other supplements, which in the investigator s opinion may interfere with the study. 
Subjects with acute liver disease or active peptic ulcer disease. 
Subjects with elevated uric acid levels greater than 10 mg/dL or gout 
Pregnancy or women currently breastfeeding. 
Female subjects taking hormonal contraceptives or hormone replacement therapy may be included in this study only if they have been on a stable dose for at least 3 months. 
BMI less than 18.5 
Subjects with weight that varies greater than 20% over the past 3 months. 
Subjects taking the following medications for at least six weeks, which may interfere with the study, will be excluded: BAS, antibiotics, anticoagulants, anticonvulsants, antiarrhythmic, Cyclosporine, Mycophenolate and Synthroid. Subjects with chronic diarrhea, gastric bypass or lap band procedures, ostomies, bowel motility problems, or other conditions that could affect intestinal fat absorption. 
Subjects initiating new medications or patients on multiple medications may also be excluded. 
Inability to swallow capsules 
Patients with a history of type I or type II diabetes or HbA1c greater than 6.5%. 
Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer.       
    

NCT02322203_exc_T1
Procedure
lipid modification therapy
NCT02322203_exc_T2
Drug
statins
NCT02322203_exc_T3
Drug
fibrates
NCT02322203_exc_T4
Drug
bile acid sequestrants
NCT02322203_exc_T5
Scope
statins, fibrates and bile acid sequestrants
NCT02322203_exc_T7
Drug
fish oil
NCT02322203_exc_T10
Condition
acute liver disease
NCT02322203_exc_T11
Condition
peptic ulcer disease
NCT02322203_exc_T12
Temporal
active
NCT02322203_exc_T13
Measurement
uric acid levels
NCT02322203_exc_T14
Value
elevated
NCT02322203_exc_T15
Value
greater than 10 mg/dL
NCT02322203_exc_T16
Condition
gout
NCT02322203_exc_T17
Condition
Pregnancy
NCT02322203_exc_T18
Person
women
NCT02322203_exc_T19
Observation
breastfeeding
NCT02322203_exc_T20
Person
Female
NCT02322203_exc_T21
Drug
hormonal contraceptives
NCT02322203_exc_T22
Procedure
hormone replacement therapy
NCT02322203_exc_T23
Qualifier
stable dose
NCT02322203_exc_T24
Temporal
for at least 3 months
NCT02322203_exc_T25
Scope
hormonal contraceptives or hormone replacement therapy
NCT02322203_exc_T27
Measurement
BMI
NCT02322203_exc_T28
Value
less than 18.5
NCT02322203_exc_T29
Measurement
weight
NCT02322203_exc_T30
Qualifier
varies greater than 20%
NCT02322203_exc_T31
Temporal
over the past 3 months
NCT02322203_exc_T32
Temporal
for at least six weeks
NCT02322203_exc_T33
Drug
BAS
NCT02322203_exc_T34
Drug
antibiotics
NCT02322203_exc_T35
Drug
anticoagulants
NCT02322203_exc_T36
Drug
anticonvulsants
NCT02322203_exc_T37
Drug
antiarrhythmic
NCT02322203_exc_T38
Drug
Cyclosporine
NCT02322203_exc_T39
Drug
Mycophenolate
NCT02322203_exc_T40
Drug
Synthroid
NCT02322203_exc_T42
Scope
BAS, antibiotics, anticoagulants, anticonvulsants, antiarrhythmic, Cyclosporine, Mycophenolate and Synthroid
NCT02322203_exc_T43
Condition
chronic diarrhea
NCT02322203_exc_T44
Procedure
gastric bypass
NCT02322203_exc_T45
Procedure
lap band procedures
NCT02322203_exc_T46
Procedure
ostomies
NCT02322203_exc_T47
Condition
bowel motility problems
NCT02322203_exc_T48
Condition
conditions that could affect intestinal fat absorption
NCT02322203_exc_T51
Condition
Inability to swallow capsules
NCT02322203_exc_T52
Condition
type II diabetes
NCT02322203_exc_T53
Condition
type I diabetes
NCT02322203_exc_T54
Measurement
HbA1c
NCT02322203_exc_T55
Value
greater than 6.5%
NCT02322203_exc_T56
Observation
history
NCT02322203_exc_T57
Scope
type I or type II diabetes or HbA1c greater than 6.5%